The FDA approved Eli Lilly’s obesity drug Zepbound, also known as tirzepatide, as the first treatment for obstructive sleep apnea in the U.S. The drug is now specifically approved for patients with obesity and moderate-to-severe OSA, a condition characterized by breathing interruptions during sleep. This approval marks the first time Zepbound has been cleared for an indication other than weight loss, potentially leading to wider insurance coverage. The drug could provide a new treatment option for those suffering from both obesity and sleep apnea, addressing the needs of patients with this common comorbidity.
Source link
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
